Gastric cancer

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 2, 2005, Pages 118-124

  Varadhachary, Gauri R ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemotherapy; Gastric cancer; Staging

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; NEW DRUG; OXALIPLATIN; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; UFT;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIARRHEA; GASTRECTOMY; HUMAN; LYMPHADENECTOMY; METASTASIS; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PROGNOSIS; SIDE EFFECT; STOMACH CANCER;

CHEMOTHERAPY, ADJUVANT; HUMANS; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS;

EID: 26044456557     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265:1287-1289.
3. Ngoan LT, Mizoue T, Fujino Y, et al. Dietary factors and stomach cancer mortality. Br J Cancer. 2002;87:37-42.
4. Tsugane S, Sasazuki S, Kobayashi M, et al. Salt and salted food intake and subsequent risk of gastric cancer among middle-aged Japanese men and women. Br J Cancer. 2004;90:128-134.
5. Sasazuki S, Inoue M, Hanaoka T, et al. Green tea consumption and subsequent risk of gastric cancer by subsite: the JPHC Study. Cancer Causes Control. 2004;15:483-491.
6. La Vecchia C, Negri E, D'Avanzo B, et al. Electric refrigerator use and gastric cancer risk. Br J Cancer. 1990;62:136-137.
7. La Vecchia C, Negri E, D'Avanzo B, et al. Food temperature and gastric cancer. Int J Cancer. 1990;46:432-434.
8. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735-6740.
9. Boissy RJ, Watson MA, Umbach DM, et al. A pilot study investigating the role of NAT1 and NAT2 polymorphisms in gastric adenocarcinoma. Int J Cancer. 2000;87:507-511.
10. Katoh T. Boissy R, Nagata N, et al. Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. Int J Cancer. 2000; 85:46-49.
11. Machado JC, Pharoah P, Sousa S, et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001;121:823-829.
12. el-Rifai W, Powell SM. Molecular and biologic basis of upper gastrointestinal malignancy. Gastric carcinoma [review]. Surg Oncol Clin N Am. 2002;11:273-291, viii.
13. Chun YS, Lindor NM, Smyrk TC, et al. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer. 2001;92:181-187.
14. Karpeh MS, Leon L, Klimstra D, et al. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg. 2000;232:362-371.
15. Green D, Ponce de Leon S, Leon-Rodriguez E, et al. Adenocarcinoma of the stomach: univariate and multivariate analysis of factors associated with survival. Am J Clin Oncol. 2002;25:84-89.
16. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med. 1999;340:908-914.
17. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Ontology Group study 9501. J Clin Oncol. 2004;22:2767-2773.
18. Allum W, Cunningham D, Weeden S, for the UK NCRI Upper GI Clinical Studies Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971) [abstract]. Proc Am Soc Clin Oncol. 2003;22:249. Abstract 998.
19. Lordick F, Stein HJ, Peschel C, et al. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg. 2004;91:540-551.
20. Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774-2780.
21. Coombes RC, Schein PS, Chilvers CE, et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol. 1990;8:1362-1369.
22. Lise M, Nitti D, Marchet A, et al. Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy. Ann Surg Oncol. 1995;2:495-501.
23. Macdonald JS, Fleming TR, Peterson RF, et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: a Southwest Oncology Group study. Ann Surg Oncol. 1995;2:488-494.
24. Avizonis VN, Buzydlowski J, Lanciano, R, et al. Treatment of adenocarcinoma of the stomach with resection, intraoperative radiotherapy, and adjuvant external beam radiation: a phase II study from Radiation Therapy Ontology Group 85-04. Ann Surg Oncol. 1995;2:295-302.
25. Skoropad VY, Berdov BA, Mardynski YS, et al. A prospective, randomized trial of pre-operative and intraoperative radiotherapy versus surgery alone in resectable gastric cancer. Eur J Surg Oncol. 2000;26:773-779.
26. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.
27. MacDonald JS, Schein PS, Woolley PV, et al. 5-fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med. 1980;93:533-536.
28. Klein HO, Wils J, Bleiberg H, et al. An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluoroufacil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer. Med Oncol Tumor Pharmacother. 1989;6:171-174.
29. Van Cutsem E, Filez L, Dewyspelaere J, et al. Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: a phase II study. Anticancer Res. 1995;15:1079-1080.
30. Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol. 2000; 11:301-306.
31. Roth AD, Maibach R, Fazio N, et al. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. Ann Oncol. 2004;15:759-764.
32. Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002;94:641-646.
33. Ajani JA, Baker J, Pisters PW, et al. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Huntingt). 2002;16:16-18.
34. Jatoi A, Tirona MT. Cha SS, et al. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Int J Gastrointest Cancer. 2002;32:115-123.
35. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol. 2004;22:658-663.
36. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003;89:2207-2212.
37. Ajani JA, Cutsem EV, Moiseyenko V, et al. Docetaxel (D), cisplatin, 5-fluorouracil compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325) [abstract]. Proc Am Soc Clin Oncol. 2003. Abstract 999.
38. Pozzo C, Bugat R, Peschel C, et al. Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastroesophageal junction adenocarcinoma: final results of a randomized phase II study [abstract]. Proc Am Soc Clin Oncol. 2001;20:134a. Abstract 531.
39. Sumpter KA, Harper-Wynne C, Cunningham D, et al. Randomised, multi-center phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: confirmation of dose escalation [abstract]. Proc Am Soc Clin Oncol. 2003;22:257. Abstract 1031.
40. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG 9205). J Clin Oncol. 2003;21:54-59.